1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
LigaChem Biosciences Inc.

LigaChem Biosciences Inc.

KKRX:141080
68,200.00
KRW
-1,200.00
(-1.73%)
-4,159.82EPS
7.00TMarket Cap
Nov 18Next Earn
LigaChem Biosciences Inc.
KRX:141080
(Korea Stock Exchange)

Recent

price

68,200.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
69.16
63.25
60.15
115.83
882.85
1,108.48
1,197.84
2,711.08
2,170.87
1,333.5
1,192.23
1,202.22
3,663.91
3,891.5
3,459.83
Revenue per Share
-248.5
-439.5
-600.5
-533.5
-780.5
-650
-1,223
640.57
-307.05
-970
-1,609
-2,595
227
-2,042
-3,795.63
Basic EPS, GAAP
-227.77
-552.41
-565.05
-592.3
-916.02
-540.46
-793.86
972.32
-796.03
-2,515.14
-424.9
-2,268.77
2,117.94
-3,589.66
-4,032.52
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
240.66
1,267.41
1,308.95
2,386.95
3,020.78
2,421.32
4,766.84
5,274.52
4,725.38
10,615.6
8,568.24
5,291.96
16,978.06
13,930.3
12,705.41
Book Value per Share
236.84
1,263.38
1,300.94
570.12
1,674.47
1,275.07
4,289.52
4,855.36
4,381.26
10,260.69
8,258.9
5,045.31
16,745.38
11,063.07
9,835.35
Tangible Book Value per Share
11
13
14
15
19
20
21
21
23
24
28
28
34
36
36
Basic Weighted Avg Shares
744
840
870
1,788
16,655
22,057
25,240
57,500
49,394
32,157
33,412
34,146
125,898
141,553
125,866
Sales/Revenue/Turnover
-436.89
-745.36
-972.01
-450.04
-60.96
-44.62
-63.3
14.64
-60.25
-86.16
-150.77
-236.7
-16.61
-75.23
-123.37
Operating Margin (%)
75
221
344
395
2,151
2,640
2,780
3,865
2,994
3,049
4,118
4,672
5,009
6,609
6,844
Depreciation Expense
-2,674
-5,835
-8,686
-8,237
-14,725
-12,934
-25,770
13,586
-6,986
-23,391
-45,092
-73,704
7,800
-74,278
-138,082
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
4.78
- -
- -
- -
- -
14.52
- -
- -
Effective Tax Rate (%)
-359.33
-694.83
-998.29
-460.58
-88.41
-58.64
-102.1
23.63
-14.14
-72.74
-134.96
-215.85
6.2
-52.47
-109.71
Profit Margin (%)
4,669
19,192
29,691
20,434
34,621
27,569
83,433
95,995
86,001
211,933
163,016
97,547
433,079
460,350
432,528
Working Capital
25
1,051
9,069
9,829
7,853
8,519
- -
2,074
3,909
9,410
216
528
339
1,691
1,648
LT Debt
3,354
18,084
20,044
43,178
60,060
49,465
105,295
115,909
112,126
258,775
219,599
148,221
615,998
541,120
500,522
Total Equity
- -
- -
- -
- -
- -
- -
- -
7.25
- -
- -
- -
- -
-4.64
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
13.18
- -
- -
- -
- -
2.12
- -
- -
Return on Capital (%)
- -
-55.94
-45.56
-26.06
-28.53
-23.89
-34.55
12.69
-6.21
-12.67
-18.95
-40.21
2.04
-13.22
-26.39
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,106
1,059
955
LT Borrowings
- -
- -
- -
LT Finance Leases
1,726
1,691
1,648
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
36
36
Market Capitalization
5,114,921
6,329,549
6,996,393

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
595,605
521,442
479,963
Cash, Cash Equivalents & STI
548,561
474,548
428,339
Accounts Receivable, Net
14,167
11,756
10,031
Inventories
161
110
95
Total Current Liabilities
66,427
61,092
47,435
Payables & Accruals
- -
- -
- -
ST Debt
1,106
1,059
955
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
52.77%
77.32%
-12.16%
Free Cash Flow
-20.11%
20.66%
-279.42%
Net Income, GAAP
-91.01%
-154.36%
-1,052.27%
Sales/Revenue/Turnover
124.42%
50.47%
12.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
31,056
30,754
30,420
33,669
125,898
2025
51,576
32,617
41,410
15,951
141,553
2026
35,888
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
336
-269
310
-149.36
227
2025
730
-839.67
-431.15
-1,497.5
-2,042
2026
-1,024.48
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
LigaChem Biosciences Inc. (KOSDAQ: 141080) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutics leveraging proprietary medicinal chemistry platforms, primarily focusing on antibody-drug conjugates (ADCs), immuno-oncology drugs, small molecule payloads, antibiotics, and anti-fibrotics for oncology, hematologic malignancies, and other unmet medical needs. The company offers next-generation ADC technologies such as its ConjuALL platform that overcomes limitations of conventional ADCs through enhanced stability, efficacy, and safety profiles; differentiated ADC candidates including HER2-ADC (Caxmotabart Entudotin), CD19-ADC (LCB73), CA242-ADC (IKS04), and FRα-ADC (IKS012); novel immuno-oncology small molecules and ADC payloads; and additional programs in antibiotics and anti-fibrotic therapies, while also providing medical devices and supplies. Founded in 2006 and headquartered in Daejeon, South Korea, with a Seoul sales office, LigaChem Biosciences operates globally through research collaborations, licensing agreements, and clinical trials primarily in South Korea, the United States, Europe, and China, targeting pharmaceutical partners and patients in oncology and related fields. In April 2024, the company changed its name from LegoChem Biosciences Inc. to LigaChem Biosciences Inc. to reflect its strategic evolution. Recent developments include a January 2025 extension of its ADC development and manufacturing collaboration with Samsung Biologics to bolster supply chain capabilities; a strategic $25 million investment announced in March 2025 acquiring a 26.6% stake (potentially up to 73.9%) in partner Iksuda Therapeutics to accelerate global clinical trials and commercialization of shared ADC pipelines like HER2-ADC and CD19-ADC; and an April 2025 R&D and licensing option agreement with 1STBIO to advance next-generation ADC payloads for first-in-class oncology programs.